Ontario multi-centre clinical trial
Rna Diagnostics (RnaDx) has initiated an Ontario multi-centre clinical trial to assess both patient health outcomes and healthcare savings related to the use of RNA Disruption Assay™ (RDA™). Through the MaRS Excellence in Clinical Innovation and Technology Evaluation (EXCITE) program, The Toronto Health Economics and Technology Assessment (THETA) initiative will perform a full pre-market assessment of the RDA technology.
The EXCITE program consists of a multi-centre clinical trial, a human factors study of biopsy procedures, a comprehensive health economics analysis of RDA healthcare savings and a qualitative study of patient and clinician attitudes toward RDA testing. The EXCITE program will help move RDA to clinic faster, and improve health outcomes for women undergoing breast cancer chemotherapy. The Honourable Deb Matthews, Minister of Health and Long-Term Care, announced the participation of RnaDx in the EXCITE program on May 30 in Toronto.
Read full news release
Dr. Ken Pritzker presents at Triple Negative Breast Cancer Conference
There was substantial positive interest in RnaDx’ RNA Disruption Assay™ (RDA™) at the Triple Negative Breast Cancer (TNBC) Conference, held in London, England in June. Dr. Ken Pritzker presented an abstract on RDA to the assembly of international breast cancer specialists. View abstract
Triple Negative Breast Cancer is an aggressive form of cancer that often affects young women. TNBC patients have poorer prognoses than other breast cancer patients. There is a dire need for a test to accurately determine the efficacy of breast cancer chemotherapy for these patients. Given their poor prognoses it is important to rapidly assess TNBC patients’ response to therapy so that non-responders may be switched from ineffective therapies to ones that may improve their chances of survival.
RDA is positioned as a useful tool to aid management of therapy for TNBC patients.
The TNBC Conference was attended by over 150 specialists from around the world who are involved in breast cancer treatment and have an interest in finding better treatment methods for this aggressive form of breast cancer.
RDA™ demonstrates healthcare cost-savings
A preliminary economic analysis of the RNA Disruption Assay™ (RDA™) demonstrates it is a cost-effective treatment strategy compared to standard of care for individuals undergoing breast cancer chemotherapy. Rna Diagnostics presented an abstract of the analysis at the Applied Research in Cancer Control conference (ARCC) in Vancouver, British Columbia in May.
The healthcare economic analysis indicates that RDA increases patient survival and lowers treatment costs for patients undergoing breast cancer chemotherapy. The key factor driving the cost-effectiveness of RDA is the ability of the test to detect individuals who are not responding to breast cancer chemotherapy.